{"id":540747,"date":"2021-04-27T20:16:01","date_gmt":"2021-04-27T20:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=540747"},"modified":"2021-04-27T20:16:01","modified_gmt":"2021-04-27T20:16:01","slug":"hunter-syndrome-market-size-share-trends-epidemiology-market-research-and-forecast-report-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hunter-syndrome-market-size-share-trends-epidemiology-market-research-and-forecast-report-2030-delveinsight_540747.html","title":{"rendered":"Hunter Syndrome Market Size, Share, Trends, Epidemiology, Market Research and Forecast Report 2030 | DelveInsight"},"content":{"rendered":"
\"Hunter<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Hunter Syndrome -Market Insights, Epidemiology and Market Forecast\u2013 2030\u2019 report delivers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\n<\/div>\n

DelveInsight launched a new report on Hunter Syndrome Market Insights, Epidemiology, and Market Forecast 2030<\/strong><\/a>.<\/p>\n

DelveInsight’s ‘Hunter Syndrome Market Insights, Epidemiology and Market Forecast– 2030<\/strong><\/a>’ report delivers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Hunter syndrome is also known as Mucopolysaccharidosis type II (MPS II). It is a condition that affects many different parts of the body and mainly affects males. It is a progressive disorder, but the rate of progression varies among affected individuals. It is a rare, X-linked disorder caused due to a deficiency of the lysosomal enzyme iduronate-2-sulfatase, which plays a major role in the catabolism of glycosaminoglycans (GAG). In patients with mucopolysaccharidosis II, glycosaminoglycans accumulate within tissues and organs, contributing to the signs and symptoms of the disease. <\/p>\n

Hunter Syndrome Epidemiology Insights:<\/strong><\/p>\n

1. The total Hunter Syndrome diagnosed prevalent population<\/strong><\/a> in the 7 major markets was found to be 1,145 in 2017.<\/p>\n

2. In the case of Hunter Syndrome patients in the United States, the diagnosed prevalent cases were found to be 503 in 2017.<\/p>\n

3. In the EU5 countries the diagnosed prevalence of Hunter Syndrome was found to be maximum in Germany with 83 cases, followed by the United Kingdom with 68 cases in 2017. While, the least number of cases were found in Spain, in 2017. The trend is expected to increase during the forecast period.<\/p>\n

Hunter Syndrome Key Pharma Players Involved:<\/strong><\/p>\n

1. JCR Pharmaceuticals<\/p>\n

2. Takeda<\/p>\n

3. Denali Therapeutics<\/p>\n

Hunter Syndrome Emerging Therapies Involved:<\/strong><\/p>\n

1. JR-141<\/p>\n

2. TAK-609<\/p>\n

3. DNL310<\/p>\n

Request for a detailed sample copy of the report: https:\/\/www.delveinsight.com\/sample-request\/hunter-syndrome-market<\/a><\/strong><\/p>\n

“The market size of Hunter Syndrome in the seven major markets is USD 376.62 Million in 2017.”<\/strong><\/p>\n

Table of Contents:<\/strong><\/p>\n

1 Key Insight
2 Executive Summary of Hunter Syndrome
3 Hunter Syndrome Market Overview at a Glance
4 Disease Background and Overview: Hunter Syndrome
5 Case Reports
6 Hunter Syndrome Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Hunter Syndrome Treatment and Medical Practices
11 Unmet needs
12 Hunter Syndrome Marketed Drugs
13 Hunter Syndrome Emerging Drugs
14 Hunter Syndrome 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Hunter Syndrome Market Drivers
19 Hunter Syndrome Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

Download our full report: https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-market<\/a><\/strong><\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Shruti Thakur
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> NV
Country:<\/strong> United States
Website:<\/strong> www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Hunter Syndrome -Market Insights, Epidemiology and Market Forecast\u2013 2030\u2019 report delivers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-540747","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=540747"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540747\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=540747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=540747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=540747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}